News

BOS-580 is an investigational, proprietary, long-acting fibroblast growth factor 21 analog as a monthly and bi-weekly treatment for patients with NASH.

Significant improvements seen in hematologic parameters, visceral volumes, and plasma biomarkers in patients with Gaucher disease, suggesting its potential as an alternative therapy, particularly for those who cannot access enzyme replacement therapy.

Use of metformin was associated with significant reductions in the risk of developing POAG beyond glycemic control, according to an analysis presented at ADA 2023.

Significant cases of missed diagnoses of iron-deficiency emphasize the need for improved screening strategies and proactive measures to address these health risks.

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.

APX3330 showed statistically significant prevention of ≥3-step binocular DRSS worsening compared to placebo, but did not meet the study's primary endpoint.

Telehealth likely will have a major place in psychiatric care in the future.

In this interview, physician assistant Hope Cook described some of the major talking points from her conference talk titled ‘Healing PA Burnout.’

For participants reporting past-year suicidal experiences, there was decreased odds of attributing their suicidal experiences to the pandemic for veterans compared to nonveterans.

Data from a pair of phase 2 trials in patients with overweight/obesity and type 2 diabetes presented at ADA 2023 suggest the GIP/GLP-1/Glucagon agonist retatrutide could provide significant weight loss and glycemic control benefits.

Optum Rx announced it will place the biosimilar adalimumab-adbm (Cyltezo) injection on its commercial formulary as a preferred brand.

A 7-year longitudinal analysis presented at ADA 2023 suggests time in range was associated with an increased risk of diabetic retinopathy in people with type 1 diabetes.

Hosts are joined by Cari Berget, RN, MPH, for a deep dive into her efforts to improve the implementation of the latest diabetes technologies in real-world settings through her role as a director of the PANTHER Program.

An analysis presented at ADA 2023 suggests autonomous artificial intelligence testing for diabetic eye diseases promoted health equity across various patient subgroups.

Data from a pair of trials presented at ADA 2023 suggests an upped dose of oral semaglutide could soon be on the horizon, with results supporting use in chronic weight management as well as type 2 diabetes.

Results from the EMPRISE study presented at ADA 2023 showed empagliflozin was associated with a 23% reduction in the risk of diabetic retinopathy progression in adults with T2D.

Ritlecitinib becomes the second JAK inhibitor approved to treat alopecia—and the first to be indicated for patients aged 12 years and older.

Communities already facing social vulnerabilities are more likely to bear the burden of increased smoke exposure.

Post hoc analysis of the topical therapy show patients receiving treatment for acne in the winter were as likely to achieve benefit as those receiving it in the summer.

The investigators found an adjusted odds ratio of 1.74 for hospitalized suicide attempts and 1.45 for those who committed suicide in individuals with recent psychiatric history.

Janssen reported significant benefit, and a tolerable profile, for the investigative drug that may become the first indicated to treat HDFN.

In this interview, Dr. Noor spoke about the contents of his conference presentation regarding the tailoring of treatment plans to patients with skin of color.

In her presentation ‘Treatment of Eczema in Pediatric Patients Under 12 Years,’ Dr. Garza-Mayers spoke on considerations for atopic dermatitis management.

At ADA 2023, we sat down with W. Timothy Garvey, MD, to learn more about the safety and efficacy of tirzepatide in the SURMOUNT-2 trial and how the results complement SURMOUNT-1.

An analysis at ADA 2023 presents novel findings on the inverse association between clinical and biochemical factors in diabetic retinopathy and age-related macular degeneration.

Often overlooked and unrecognized, the mental health challenges accompanying type 1 diabetes are becoming a focal point of discussion for many in the field, including Mark Heyman, PhD, who joined Diana Isaacs, PharmD, and Natalie Bellini, DNP, for a special ADA 2023 edition of Diabetes Dialogue.

In an interview at ADA 2023, Aggarwal discusses the efficacy of sotagliflozin on heart failure-related outcomes independent of A1c and the greater implications of these findings.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.